Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells 24,610 Shares of Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 24,610 shares of the company’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $2.05, for a total transaction of $50,450.50. Following the completion of the sale, the chief executive officer now directly owns 1,977,170 shares in the company, valued at $4,053,198.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Checkpoint Therapeutics Stock Up 4.4 %

NASDAQ:CKPT traded up $0.09 during trading hours on Friday, reaching $2.15. The company had a trading volume of 252,621 shares, compared to its average volume of 477,131. Checkpoint Therapeutics, Inc. has a twelve month low of $1.30 and a twelve month high of $3.62. The firm has a market cap of $76.73 million, a price-to-earnings ratio of -0.78 and a beta of 1.13. The business’s 50-day simple moving average is $1.78 and its two-hundred day simple moving average is $1.93.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its earnings results on Friday, May 10th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.04. As a group, equities analysts predict that Checkpoint Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $34.00 price target on shares of Checkpoint Therapeutics in a report on Monday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Checkpoint Therapeutics currently has an average rating of “Buy” and an average price target of $22.60.

Hedge Funds Weigh In On Checkpoint Therapeutics

A number of institutional investors have recently modified their holdings of the company. Armistice Capital LLC increased its stake in Checkpoint Therapeutics by 46.1% during the 3rd quarter. Armistice Capital LLC now owns 2,064,000 shares of the company’s stock valued at $3,509,000 after purchasing an additional 651,000 shares in the last quarter. Choreo LLC bought a new stake in shares of Checkpoint Therapeutics during the fourth quarter worth about $44,000. B. Riley Wealth Advisors Inc. raised its holdings in shares of Checkpoint Therapeutics by 232.3% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 163,350 shares of the company’s stock worth $374,000 after acquiring an additional 114,200 shares during the last quarter. Magnus Financial Group LLC bought a new position in Checkpoint Therapeutics in the 4th quarter valued at about $55,000. Finally, Sabby Management LLC acquired a new position in Checkpoint Therapeutics during the 3rd quarter valued at about $349,000. 22.00% of the stock is owned by institutional investors and hedge funds.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.